All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

  TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub
Brought to you by Scientific Education Support

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

To help navigate the exciting content being presented at the EHA 2025 Congress, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD. 

EHA 2025 top abstracts in GvHD

Abstracts

Abstract #DayTimeTitleSpeaker
S255Thurs17:00–17:15JAK/ROCK inhibition with rovadicitinib suppresses murine and human acute graft-versus-host disease: The results of preclinical and phase 1b studyYanmin Zhao
S260Fri17:00–17:15Pooled fecal allogenic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease : Results from the early access program in EuropeMohamad Mohty
S103Sat12:30–12:45A phase 3 randomised trial of post-transplant cyclophosphamide for GvHD Prophylaxis in matched sibling donor peripheral blood stem cell transplantation: The ALLG BM12 CAST trialDavid Curtis

 

Posters

PF392Comparison of different doses of rabbit anti-thymocyte globulin (ATG-T) and anti-T-lymphocyte globulin (ATLG) in TBI-based myeloablative conditioning for haploidentical transplantation in acute lymphoblastic leukemia patientsYue Lu
PF1034Immune modulation in leukemia patients after hematopoetic stem cell transplantation with acute or chronic graft vs host disease (a/cGvHD): 12-week extracorporeal photopheresis (ECP) reduces inflammatory and enhances inhibitory immune reactive cellsAnying Huang
PF1042Unmet needs in cGvHD management: Real-world analysis of baseline and disease characteristics in European and Spanish patients previously treated with 2 to 5 lines of therapyCarlos Solano
PF1043Effect of anti-thymocyte globulin and post-transplant cyclophosphamide on GvHD outcomes in female-to-male matched unrelated donor allogeneic stem cell transplantation for acute leukemiaNihar Desai
PF1072Efficacy and safety of belumosudil monotherapy and combination with ruxolitinib in refractory chronic graft-versus-host-disease: A single centre, real-world experienceVinay Anand Guntiboina
PF1090Trial in progress: A randomized, open-label, phase 3 study of axatilimab versus best available therapy in patients with chronic graft-versus-host disease after ≥2 prior lines of systemic therapyMi Kwon
PS2027A randomized trial of three GvHD prophylaxis regimens in haploidentical peripheral blood stem cell transplant: Antithymocyte globulin, posttransplant cyclophosphamide, and low-dose combination therapyYannan Jia
PS2031MAAT033 to ensure optimal gut microbiota to improve survival in patients receiving allogeneic HCT: PHOEBUS trialNatalia Gemperle Ortiz

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2025Graft-versus-host disease

Related articles

ASH 2024 abstracts: What’s hot in GvHD?

ASH 2024 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 66th ASH Annual Meeting and Exposition, the GvHD Hub Steering Committee members provided their recommendations for t...

Dec 2, 2024

51st Annual Meeting of the EBMT congress coverage: GvHD prophylaxis

51st Annual Meeting of the EBMT congress coverage: GvHD prophylaxis

Catch up with our live social media coverage of GvHD prophylaxis from the 51st Annual Meeting of the EBMT.

Mar 22, 2025

Newsletter

Subscribe to get the best content delivered to your inbox